Dicot Pharma AB

Dicot Pharma AB operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.0. The company's liquidity position is strong, with a current ratio of 7.06, indicating that it holds significantly more current assets than current liabilities. However, the company's liquidity is not supported by positive operating cash flow, which was negative at -85.85 million SEK in the latest reporting period. Profitability metrics for Dicot Pharma are negative, with a return on equity of -109.38% and a return on assets of -93.88%. These figures are well below the industry median for pharmaceutical companies, which typically exhibit positive returns due to the high-margin nature of drug development and sales. The company reported a net loss of 80.24 million SEK, with operating income also in the red at -82.46 million SEK. Gross profit was similarly negative at -72.00 million SEK, suggesting that the company is not yet achieving cost efficiencies or pricing power in its product offerings. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification beyond the Nordic region. This concentration increases exposure to regional economic fluctuations and regulatory changes. There is no indication of multiple revenue streams or international operations in the latest financial data. Growth trajectory for Dicot Pharma is currently negative, with a net loss of 80.24 million SEK and a free cash flow of -80.24 million SEK. The company has not provided forward-looking guidance for the next fiscal year, and there is no indication of a near-term reversal in its financial performance. The lack of positive cash flow and the absence of long-term debt suggest that the company is relying on equity financing to sustain operations. Risk factors for Dicot Pharma include its negative profitability and lack of operating cash flow, which could limit its ability to fund future operations or invest in product development. The company has not issued any recent equity, and there are no immediate dilution risks based on current filings. However, the absence of long-term debt and the presence of a strong equity base provide some buffer against short-term liquidity pressures. Recent events for Dicot Pharma include the continued focus on its dermatological product portfolio, with no major new product launches or regulatory approvals disclosed in the latest financial filings. The company has not issued any material risk factors in its 10-K equivalent or other public disclosures that would suggest a significant change in its business model or strategic direction.